ESR1 and breast cancer: Risk of late recurrence in patients with ER+ breast cancer is dependent on initial clinicopathological diagnosis; however, even those with low-grade node-negative (T1N0) tumors have a 10–17% risk of distant recurrence in the following 5–20 years2.